Viracta Therapeutics (VIRX) Announces Wind Down of Operations Feb 5, 2025 05:00PM
Viracta Therapeutics (VIRX) Announces Closure of NAVAL-1 Clinical Trial and Exploration of Strategic Alternatives Dec 26, 2024 04:30PM
Viracta Therapeutics, Inc. (VIRX) Reports In-Line Q3 EPS Nov 13, 2024 04:11PM
Viracta Therapeutics (VIRX) Announces Reprioritization of Resources to Enhance Focus on Nana-val Development Program Nov 6, 2024 04:58PM
Leerink Partners Downgrades Viracta Therapeutics (VIRX) to Market Perform Aug 16, 2024 02:10AM


Aug 15, 2024 06:16AM Viracta Therapeutics (VIRX) PT Lowered to $4 at RBC Capital
Aug 14, 2024 08:04AM Viracta Therapeutics, Inc. (VIRX) Tops Q2 EPS by 12c
Aug 14, 2024 07:00AM Viracta Therapeutics (VIRX) Reports Positive Data from the Phase 2 NAVAL-1 Trial